Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Ken Uchibori; Naohiko Inase; Mitsugu Araki; Mayumi Kamada; Shigeo Sato; Yasushi Okuno; Naoya Fujita; Ryohei Katayama

doi:10.1038/ncomms14768

Nature Communications (Mar 2017)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Ken Uchibori,
Naohiko Inase,
Mitsugu Araki,
Mayumi Kamada,
Shigeo Sato,
Yasushi Okuno,
Naoya Fujita,
Ryohei Katayama

Affiliations

Ken Uchibori: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Naohiko Inase: Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Mitsugu Araki: RIKEN Advanced Institute for Computational Science
Mayumi Kamada: Graduate School of Medicine, Kyoto University
Shigeo Sato: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Yasushi Okuno: RIKEN Advanced Institute for Computational Science
Naoya Fujita: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ryohei Katayama: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research

DOI: https://doi.org/10.1038/ncomms14768
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 16

Abstract

Read online

Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal